NZ332341A - Quinoline carboxamides as TNF inhibitors and as PDE-IV inhibitors - Google Patents
Quinoline carboxamides as TNF inhibitors and as PDE-IV inhibitorsInfo
- Publication number
- NZ332341A NZ332341A NZ332341A NZ33234197A NZ332341A NZ 332341 A NZ332341 A NZ 332341A NZ 332341 A NZ332341 A NZ 332341A NZ 33234197 A NZ33234197 A NZ 33234197A NZ 332341 A NZ332341 A NZ 332341A
- Authority
- NZ
- New Zealand
- Prior art keywords
- optionally substituted
- inhibitors
- alkyl
- nor7
- heterocycloalkyl
- Prior art date
Links
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 title 1
- ZEXKKIXCRDTKBF-UHFFFAOYSA-N quinoline-2-carboxamide Chemical class C1=CC=CC2=NC(C(=O)N)=CC=C21 ZEXKKIXCRDTKBF-UHFFFAOYSA-N 0.000 title 1
- 229940046728 tumor necrosis factor alpha inhibitor Drugs 0.000 title 1
- 239000002451 tumor necrosis factor inhibitor Substances 0.000 title 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 2
- -1 CO2R11 Chemical group 0.000 abstract 1
- 101100440695 Dictyostelium discoideum corB gene Proteins 0.000 abstract 1
- 102000018594 Tumour necrosis factor Human genes 0.000 abstract 1
- 108050007852 Tumour necrosis factor Proteins 0.000 abstract 1
- 102000011017 Type 4 Cyclic Nucleotide Phosphodiesterases Human genes 0.000 abstract 1
- 108010037584 Type 4 Cyclic Nucleotide Phosphodiesterases Proteins 0.000 abstract 1
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 125000004438 haloalkoxy group Chemical group 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 125000004475 heteroaralkyl group Chemical group 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 125000004446 heteroarylalkyl group Chemical group 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000000547 substituted alkyl group Chemical group 0.000 abstract 1
- 125000003107 substituted aryl group Chemical group 0.000 abstract 1
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 abstract 1
- 125000004001 thioalkyl group Chemical group 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Communicable Diseases (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pulmonology (AREA)
- Virology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Quinoline Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9610506.9A GB9610506D0 (en) | 1996-05-20 | 1996-05-20 | Novel compounds |
| GBGB9623234.3A GB9623234D0 (en) | 1996-11-07 | 1996-11-07 | Novel compounds |
| GBGB9626883.4A GB9626883D0 (en) | 1996-12-24 | 1996-12-24 | Compounds |
| GBGB9708072.5A GB9708072D0 (en) | 1997-04-22 | 1997-04-22 | Compounds |
| PCT/GB1997/001359 WO1997044036A1 (en) | 1996-05-20 | 1997-05-20 | Quinoline carboxamides as tnf inhibitors and as pde-iv inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ332341A true NZ332341A (en) | 2000-05-26 |
Family
ID=27451451
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ332341A NZ332341A (en) | 1996-05-20 | 1997-05-20 | Quinoline carboxamides as TNF inhibitors and as PDE-IV inhibitors |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US5804588A (enExample) |
| EP (1) | EP0952832B1 (enExample) |
| JP (1) | JP2000510865A (enExample) |
| KR (1) | KR20000065219A (enExample) |
| CN (1) | CN1148189C (enExample) |
| AT (1) | ATE406163T1 (enExample) |
| AU (1) | AU722472B2 (enExample) |
| BR (1) | BR9709015A (enExample) |
| CA (1) | CA2252531A1 (enExample) |
| CZ (1) | CZ296163B6 (enExample) |
| DE (1) | DE69738949D1 (enExample) |
| IL (1) | IL126557A (enExample) |
| NO (1) | NO312099B1 (enExample) |
| NZ (1) | NZ332341A (enExample) |
| PL (1) | PL329922A1 (enExample) |
| RU (1) | RU2170730C2 (enExample) |
| SK (1) | SK283162B6 (enExample) |
| TR (1) | TR199802385T2 (enExample) |
| WO (1) | WO1997044036A1 (enExample) |
Families Citing this family (87)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6008230A (en) * | 1995-10-16 | 1999-12-28 | Fujisawa Pharmaceutical Co., Ltd. | Quinoline compounds as H+ -ATPases |
| GB9712761D0 (en) * | 1997-06-17 | 1997-08-20 | Chiroscience Ltd | Quinolines and their therapeutic use |
| US6262070B1 (en) | 1998-11-04 | 2001-07-17 | Darwin Discovery Ltd. | Heterocyclic compounds and their therapeutic use |
| GB9824160D0 (en) * | 1998-11-04 | 1998-12-30 | Darwin Discovery Ltd | Heterocyclic compounds and their therapeutic use |
| SI1212089T1 (sl) | 1999-08-21 | 2006-08-31 | Altana Pharma Ag | Sinergisticna kombinacija roflumilasta in salmeterola |
| WO2001032658A1 (en) * | 1999-11-02 | 2001-05-10 | Ajinomoto Co., Inc. | Polyazanaphthalene compound and medicinal use thereof |
| JP4603646B2 (ja) * | 1999-11-15 | 2010-12-22 | 富士フイルムファインケミカルズ株式会社 | 新規なジピリジル誘導体 |
| US7217722B2 (en) | 2000-02-01 | 2007-05-15 | Kirin Beer Kabushiki Kaisha | Nitrogen-containing compounds having kinase inhibitory activity and drugs containing the same |
| GB0003256D0 (en) * | 2000-02-11 | 2000-04-05 | Darwin Discovery Ltd | Heterocyclic compounds and their therapeutic use |
| US6521618B2 (en) | 2000-03-28 | 2003-02-18 | Wyeth | 3-cyanoquinolines, 3-cyano-1,6-naphthyridines, and 3-cyano-1,7-naphthyridines as protein kinase inhibitors |
| DE10035928A1 (de) | 2000-07-21 | 2002-03-07 | Asta Medica Ag | Neue Heteroaryl-Derivate und deren Verwendung als Arzneimittel |
| EP1310488A4 (en) * | 2000-08-09 | 2005-08-10 | Mitsubishi Pharma Corp | CONDENSED BICYCLIC AMIDE COMPOUNDS AND MEDICAL USES THEREOF |
| US6953774B2 (en) | 2000-08-11 | 2005-10-11 | Applied Research Systems Ars Holding N.V. | Methods of inducing ovulation |
| JP2002300373A (ja) * | 2001-03-30 | 2002-10-11 | Minolta Co Ltd | 画像処理方法、画像処理装置、記録媒体及びプログラム |
| CA2447619A1 (en) | 2001-05-23 | 2002-11-28 | Tanabe Seiyaku Co., Ltd. | A composition for accelerating bone fracture healing |
| WO2002094320A1 (en) * | 2001-05-23 | 2002-11-28 | Tanabe Seiyaku Co., Ltd. | Therapeutic compositions for repairing chondropathy |
| DE60215178T2 (de) | 2001-07-16 | 2007-08-23 | Astrazeneca Ab | Quinolin-derivate und ihre verwendung als inhibitoren der tyrosine kinase |
| EP1417204B1 (en) * | 2001-08-15 | 2006-01-18 | E. I. du Pont de Nemours and Company | Ortho-heterocyclic substituted aryl amides for controlling invertebrate pests |
| ES2293965T3 (es) | 2001-12-14 | 2008-04-01 | Laboratoires Serono Sa | Metodo de inducir la ovulacion utilizando un modulador no polipeptidico de los niveles de camp. |
| MY140561A (en) | 2002-02-20 | 2009-12-31 | Nycomed Gmbh | Dosage form containing pde 4 inhibitor as active ingredient |
| SE0200920D0 (sv) * | 2002-03-25 | 2002-03-25 | Astrazeneca Ab | Novel compounds |
| ES2195785B1 (es) * | 2002-05-16 | 2005-03-16 | Almirall Prodesfarma, S.A. | Nuevos derivados de piridazin-3(2h)-ona. |
| AU2002950217A0 (en) | 2002-07-16 | 2002-09-12 | Prana Biotechnology Limited | 8- Hydroxy Quinoline Derivatives |
| ES2211344B1 (es) * | 2002-12-26 | 2005-10-01 | Almirall Prodesfarma, S.A. | Nuevos derivados de piridazin-3(2h)-ona. |
| TWI324150B (en) * | 2003-02-28 | 2010-05-01 | Novartis Ag | Process for preparing 5-[(r)-2-(5,6-diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-(1h)-quinolin-2-one salt |
| JP2006522151A (ja) | 2003-04-01 | 2006-09-28 | アプライド リサーチ システムズ エーアールエス ホールディング ナームロゼ フェンノートシャップ | 不妊症におけるホスホジエステラーゼ阻害剤 |
| TWI324151B (en) * | 2003-04-02 | 2010-05-01 | Novartis Ag | Process for the preparation of 5-(haloacetyl)-8-substituted oxy-(1h)-quinolin-2-ones |
| RU2350354C2 (ru) * | 2003-05-29 | 2009-03-27 | Астразенека Аб | ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ АНТАГОНИСТ Р2Х7 РЕЦЕПТОРА И ФАКТОР НЕКРОЗА ОПУХОЛИ α |
| US20070281931A1 (en) * | 2003-05-29 | 2007-12-06 | Nigel Boughton-Smith | Pharmaceutical Composition Containing a P2x7 Receptor Antagonist and Methotrexate |
| EP1644041A1 (en) * | 2003-05-29 | 2006-04-12 | AstraZeneca AB | A pharmaceutical composition comprising a p2x7 antagonist and sulfasalazine |
| GB0312609D0 (en) * | 2003-06-02 | 2003-07-09 | Astrazeneca Ab | Novel compounds |
| SE0302139D0 (sv) * | 2003-07-28 | 2003-07-28 | Astrazeneca Ab | Novel compounds |
| SE0302192D0 (sv) * | 2003-08-08 | 2003-08-08 | Astrazeneca Ab | Novel compounds |
| CA2538591A1 (en) * | 2003-09-15 | 2005-03-31 | Schering Corporation | Synthesis of quinoline 5-carboxamides useful for the preparation of pde iv inhibitors |
| SE0302488D0 (sv) * | 2003-09-18 | 2003-09-18 | Astrazeneca Ab | New combination |
| AU2004298486A1 (en) | 2003-12-12 | 2005-06-30 | Wyeth | Quinolines useful in treating cardiovascular disease |
| DK2666481T3 (en) * | 2003-12-26 | 2019-02-25 | Masatoshi Hagiwara | A method for regulating the phosphorylation of SR protein and antiviral agents comprising an SR protein activity regulator as the active ingredient |
| EA010369B1 (ru) | 2004-02-04 | 2008-08-29 | Пфайзер Продактс Инк. | Замещенные хинолиновые соединения |
| WO2005097058A2 (en) * | 2004-04-01 | 2005-10-20 | F. Hoffmann-La Roche Ag | Cyclodextrin inclusions complexes of pyrimidine-2,4,6-triones |
| PE20060241A1 (es) * | 2004-05-18 | 2006-04-01 | Schering Corp | 2-quinolil-oxazoles sustituidos como inhibidores de pde4 |
| ES2251866B1 (es) * | 2004-06-18 | 2007-06-16 | Laboratorios Almirall S.A. | Nuevos derivados de piridazin-3(2h)-ona. |
| ES2251867B1 (es) * | 2004-06-21 | 2007-06-16 | Laboratorios Almirall S.A. | Nuevos derivados de piridazin-3(2h)-ona. |
| GB0413960D0 (en) * | 2004-06-22 | 2004-07-28 | Novartis Ag | Organic compounds |
| WO2006002421A2 (en) * | 2004-06-24 | 2006-01-05 | Vertex Pharmaceuticals Incorporated | Modulators of atp-binding cassette transporters |
| US8354427B2 (en) | 2004-06-24 | 2013-01-15 | Vertex Pharmaceutical Incorporated | Modulators of ATP-binding cassette transporters |
| SA05260265A (ar) * | 2004-08-30 | 2005-12-03 | استرازينيكا ايه بي | مركبات جديدة |
| AR051213A1 (es) * | 2004-10-12 | 2006-12-27 | Actelion Pharmaceuticals Ltd | 1-(2-(4-bencil-4-hidroxi-piperidin-1-il)-etil)-3-(2-metil-quinolin-4-il)-urea como una sal sulfato cristalina |
| ATE517882T1 (de) * | 2004-10-19 | 2011-08-15 | Hoffmann La Roche | Chinolinderivate |
| SE0402925D0 (sv) * | 2004-11-30 | 2004-11-30 | Astrazeneca Ab | Novel Compounds |
| EP1917245A1 (de) | 2005-08-21 | 2008-05-07 | Abbott GmbH & Co. KG | Heterocyclische verbindungen und ihre verwendung als bindungspartner für 5-ht5-rezeptoren |
| EP2258358A3 (en) | 2005-08-26 | 2011-09-07 | Braincells, Inc. | Neurogenesis with acetylcholinesterase inhibitor |
| US7678363B2 (en) | 2005-08-26 | 2010-03-16 | Braincells Inc | Methods of treating psychiatric conditions comprising administration of muscarinic agents in combination with SSRIs |
| EP2377530A3 (en) | 2005-10-21 | 2012-06-20 | Braincells, Inc. | Modulation of neurogenesis by PDE inhibition |
| EP1942879A1 (en) | 2005-10-31 | 2008-07-16 | Braincells, Inc. | Gaba receptor mediated modulation of neurogenesis |
| US20090105272A1 (en) * | 2005-12-24 | 2009-04-23 | Grootenhuis Peter D J | Prodrugs of modulators of ABC transporters |
| AU2006332726B2 (en) * | 2005-12-28 | 2012-12-13 | Vertex Pharmaceuticals Incorporated. | Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
| KR100821649B1 (ko) * | 2006-01-24 | 2008-04-11 | 서울시립대학교 산학협력단 | 클리오퀴놀을 유효성분으로 포함하는 ＨＩＦ-1α 활성제 |
| US20100216734A1 (en) | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
| WO2007134136A2 (en) | 2006-05-09 | 2007-11-22 | Braincells, Inc. | Neurogenesis by modulating angiotensin |
| NZ574070A (en) * | 2006-07-11 | 2011-12-22 | Schering Corp | Xinafoate salt of a substituted 5-oxazol-2-yl-quinoline compound |
| US20100056791A1 (en) | 2006-09-01 | 2010-03-04 | Yasushi Kohno | Pyrazolopyridine carboxamide derivative and phosphodiesterase (pde) inhibitor containing the same |
| US20100184806A1 (en) | 2006-09-19 | 2010-07-22 | Braincells, Inc. | Modulation of neurogenesis by ppar agents |
| CL2007003874A1 (es) * | 2007-01-03 | 2008-05-16 | Boehringer Ingelheim Int | Compuestos derivados de benzamida; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar enfermedades cardiovasculares, hipertension, aterosclerosis, reestenosis, ictus, insuficiencia cardiaca, lesion isquemica, hipertensio |
| ES2306595B1 (es) * | 2007-02-09 | 2009-09-11 | Laboratorios Almirall S.A. | Sal de napadisilato de 5-(2-((6-(2,2-difluoro-2-feniletoxi)hexil)amino)-1-hidroxietil)-8-hidroxiquinolin-2(1h)-ona como agonista del receptor adrenergico beta2. |
| ES2320954B1 (es) * | 2007-03-02 | 2010-03-16 | Laboratorio Almirall S.A. | Nuevo procedimiento de preparacion de 3-metil-4-fenilisoxazolo (3,4-d)iridazin-7(6h)-ona. |
| ES2388454T3 (es) * | 2007-03-22 | 2012-10-15 | Astrazeneca Ab | Derivados de quinolina para el tratamiento de enfermedades inflamatorias |
| US9321730B2 (en) | 2007-08-21 | 2016-04-26 | The Hong Kong Polytechnic University | Method of making and administering quinoline derivatives as anti-cancer agents |
| US8106073B2 (en) | 2007-11-30 | 2012-01-31 | Astrazeneca Ab | Quinoline derivatives 057 |
| US20100074949A1 (en) | 2008-08-13 | 2010-03-25 | William Rowe | Pharmaceutical composition and administration thereof |
| US12458635B2 (en) | 2008-08-13 | 2025-11-04 | Vertex Pharmaceuticals Incorporated | Pharmaceutical composition and administrations thereof |
| US20100216805A1 (en) | 2009-02-25 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
| AU2010226400B2 (en) | 2009-03-20 | 2016-07-14 | Vertex Pharmaceuticals Incorporated | Process for making modulators of cystic fibrosis transmembrane conductance regulator |
| JP2011042643A (ja) * | 2009-07-24 | 2011-03-03 | Bayer Cropscience Ag | 殺虫性カルボキサミド類 |
| CA2796826A1 (en) | 2010-05-10 | 2011-11-17 | Gilead Sciences, Inc. | Bifunctional quinoline derivatives |
| AR081377A1 (es) | 2010-05-10 | 2012-08-29 | Gilead Sciences Inc | Compuestos de pirazolopiridina bifuncionales |
| US20140275224A1 (en) * | 2010-11-05 | 2014-09-18 | Regents Of The University Of Minnesota | Cytosine deaminase modulators for enhancement of dna transfection |
| US8802700B2 (en) | 2010-12-10 | 2014-08-12 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-Binding Cassette transporters |
| CN102603628B (zh) | 2010-12-22 | 2016-08-17 | 香港理工大学 | 作为抗癌试剂的喹啉衍生物 |
| US20150119399A1 (en) | 2012-01-10 | 2015-04-30 | President And Fellows Of Harvard College | Beta-cell replication promoting compounds and methods of their use |
| CA2865519C (en) | 2012-02-27 | 2018-01-02 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions comprising a solid dispersion of n-[2,4-bis(1,1-dimethylethyl0-5-hydroxyphenyl-1]-1,4-dihydro-4-oxoquinolone-3-carboxamide for treating cystic fibrosis |
| CN103285373A (zh) * | 2013-05-30 | 2013-09-11 | 苏州普罗达生物科技有限公司 | 肿瘤坏死因子-α多肽抑制剂制备及其应用 |
| CN103254291B (zh) * | 2013-05-30 | 2014-06-25 | 常州亚当生物技术有限公司 | 肿瘤坏死因子-α多肽抑制剂及其应用 |
| SG10201704327RA (en) * | 2013-10-14 | 2017-06-29 | Eisai R&D Man Co Ltd | Selectively substituted quinoline compounds |
| CN107250113B (zh) | 2014-10-07 | 2019-03-29 | 弗特克斯药品有限公司 | 囊性纤维化跨膜传导调节蛋白的调节剂的共晶 |
| RU2624906C2 (ru) * | 2015-12-22 | 2017-07-10 | федеральное государственное бюджетное учреждение "Федеральный научно-исследовательский центр эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи" Министерства здравоохранения Российской Федерации | Производные 2-хинальдинкарбоновой кислоты и их противогриппозная активность |
| WO2019053015A1 (en) | 2017-09-13 | 2019-03-21 | Syngenta Participations Ag | MICROBIOCIDE DERIVATIVES OF QUINOLINE (THIO) CARBOXAMIDE |
| CN107812006A (zh) * | 2017-11-13 | 2018-03-20 | 全椒先奇医药科技有限公司 | 一种治疗急性肾衰药物组合物及其应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2517229A1 (de) * | 1975-04-18 | 1976-10-28 | Boehringer Mannheim Gmbh | Phenylalkylcarbonsaeure-derivate und verfahren zu ihrer herstellung |
| US4186201A (en) * | 1977-02-07 | 1980-01-29 | Riker Laboratories, Inc. | Methods of using 8(tetrazol-5-ylcarbamoyl)isoquinoline compounds |
| US4147694A (en) * | 1977-02-07 | 1979-04-03 | Riker Laboratories, Inc. | 8-(1H-Tetrazol-5-yl-carbamoyl)quinoline compounds |
| JPH068292B2 (ja) * | 1985-05-07 | 1994-02-02 | アルカロイダ ベギエスゼティ ギャル | トリアゾリルキノリン誘導体 |
| ES2104862T3 (es) * | 1991-02-07 | 1997-10-16 | Roussel Uclaf | Derivados biciclicos nitrogenados, su procedimiento de preparacion, sus productos intermedios obtenidos, su aplicacion como medicamentos y composiciones farmaceuticas que los contienen. |
| US5455252A (en) * | 1993-03-31 | 1995-10-03 | Syntex (U.S.A.) Inc. | Optionally substituted 6,8-quinolines |
| SE9302490D0 (sv) * | 1993-07-26 | 1993-07-26 | Kabi Pharmacia Ab | New use of old drugs |
-
1997
- 1997-05-20 IL IL12655797A patent/IL126557A/en not_active IP Right Cessation
- 1997-05-20 NZ NZ332341A patent/NZ332341A/xx unknown
- 1997-05-20 SK SK1605-98A patent/SK283162B6/sk unknown
- 1997-05-20 EP EP97923191A patent/EP0952832B1/en not_active Expired - Lifetime
- 1997-05-20 TR TR1998/02385T patent/TR199802385T2/xx unknown
- 1997-05-20 AU AU29058/97A patent/AU722472B2/en not_active Ceased
- 1997-05-20 US US08/859,508 patent/US5804588A/en not_active Expired - Fee Related
- 1997-05-20 RU RU98123074/04A patent/RU2170730C2/ru not_active IP Right Cessation
- 1997-05-20 CA CA002252531A patent/CA2252531A1/en not_active Abandoned
- 1997-05-20 AT AT97923191T patent/ATE406163T1/de not_active IP Right Cessation
- 1997-05-20 PL PL97329922A patent/PL329922A1/xx unknown
- 1997-05-20 CN CNB97194735XA patent/CN1148189C/zh not_active Expired - Fee Related
- 1997-05-20 KR KR1019980709279A patent/KR20000065219A/ko not_active Ceased
- 1997-05-20 BR BR9709015A patent/BR9709015A/pt not_active IP Right Cessation
- 1997-05-20 WO PCT/GB1997/001359 patent/WO1997044036A1/en not_active Ceased
- 1997-05-20 DE DE69738949T patent/DE69738949D1/de not_active Expired - Fee Related
- 1997-05-20 JP JP09541788A patent/JP2000510865A/ja active Pending
- 1997-05-20 CZ CZ0365198A patent/CZ296163B6/cs not_active IP Right Cessation
-
1998
- 1998-11-19 NO NO19985376A patent/NO312099B1/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN1148189C (zh) | 2004-05-05 |
| IL126557A0 (en) | 1999-08-17 |
| PL329922A1 (en) | 1999-04-26 |
| EP0952832A1 (en) | 1999-11-03 |
| SK283162B6 (sk) | 2003-03-04 |
| BR9709015A (pt) | 1999-08-03 |
| SK160598A3 (en) | 1999-12-10 |
| AU722472B2 (en) | 2000-08-03 |
| NO985376L (no) | 1998-11-19 |
| WO1997044036A1 (en) | 1997-11-27 |
| IL126557A (en) | 2002-09-12 |
| CZ365198A3 (cs) | 1999-03-17 |
| CZ296163B6 (cs) | 2006-01-11 |
| CA2252531A1 (en) | 1997-11-27 |
| NO985376D0 (no) | 1998-11-19 |
| CN1219131A (zh) | 1999-06-09 |
| ATE406163T1 (de) | 2008-09-15 |
| NO312099B1 (no) | 2002-03-18 |
| JP2000510865A (ja) | 2000-08-22 |
| TR199802385T2 (xx) | 1999-04-21 |
| KR20000065219A (ko) | 2000-11-06 |
| DE69738949D1 (de) | 2008-10-09 |
| US5804588A (en) | 1998-09-08 |
| EP0952832B1 (en) | 2008-08-27 |
| RU2170730C2 (ru) | 2001-07-20 |
| AU2905897A (en) | 1997-12-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ332341A (en) | Quinoline carboxamides as TNF inhibitors and as PDE-IV inhibitors | |
| NZ332340A (en) | 4-(aryl or heteroaryl) substituted benzofurancarboxamide derivatives and medicaments | |
| MY113208A (en) | Pharmaceutical and compositions inhibiting kinases | |
| CA2192645A1 (en) | Tri-substituted phenyl derivatives useful as pde iv inhibitors | |
| NZ514095A (en) | Amide compounds and medicinal use thereof | |
| MX9804107A (es) | Derivados de quinolina. | |
| IL104024A (en) | 4-pyrimidinyl and pyridinyl derivatives of indol-3-yl- alkyl piperazines and antimigraine pharmaceutical compositions containing them | |
| IL120584A0 (en) | 1,2-diphenylpyrrole derivatives and pharmaceutical compositions containing the same | |
| GB9413975D0 (en) | New heterobicyclic derivatives | |
| IL95568A0 (en) | N-substituted-4-pyrimidinamines and pyrimidinidiamines,process for their preparation and pharmaceutical compositions containing them | |
| CA2252907A1 (en) | Novel 2,3 disubstituted-4(3h)-quinazolinones | |
| HUP0401729A2 (hu) | IV típusú foszfodiészteráz inhibitor hatású alkin-aril-naftiridin-4(1H)-on-származékok és ezeket tartalmazó gyógyszerkészítmények | |
| MY131193A (en) | 7-(2-aminoethyl)-benzothiazolones | |
| EP0322738A3 (en) | Benzylidene-malononitrile derivatives for the inhibition of proliferative processes in mammalian cells | |
| MY116952A (en) | 4 substituted 2-carboxy-tetrahydroquinoline derivatives, pharmaceutical compositions comprising them and process for their preparation | |
| NZ332481A (en) | 5-[2,4-diaminopyrimidinylmethyl]phenyl substituted propanone (or propenone) isoquinoline derivatives and medicaments | |
| AU5795694A (en) | New bicyclic nitrogen compounds, process for preparing them and pharmaceutical compositions containing them | |
| DK528889A (da) | Substituerede quinolinderivater og fremgangsmaade til fremstilling deraf, mellemprodukter til anvendelse ved deres fremstilling og farmaceutiske midler indeholdende derivaterne | |
| AU9426098A (en) | Azetidinone derivatives for the treatment of hcmv infections | |
| AU4555800A (en) | Use of 2,4-diamino-3-hydroxycarboxylic acid derivatives as proteasome inhibitors | |
| CA2317673A1 (en) | Novel allylthiopyridazine derivatives and process for preparing the same | |
| EP0270093A3 (en) | Lactam derivatives, processes for the preparation thereof, pharmaceutical compositions comprising the same, and the use of such derivatives for the manufacture of a medicament having valuable therapeutic properties | |
| AU654125B2 (en) | Novel diphenylthyazole derivative | |
| AU6063398A (en) | Pyrrolidine derivative, anti-ulcer drug, and antibacterial drug | |
| AU546260B2 (en) | Diphenylbutyl-1-acylpiperazines |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RENW | Renewal (renewal fees accepted) | ||
| RENW | Renewal (renewal fees accepted) |